May 22, 2023 07:22 AM EDTUpdated 07:42 AM
R&D
Pharma

Al­ny­lam up­dates its pitch for ex­pand­ed On­pat­tro la­bel with 18-month PhI­II da­ta

Katherine Lewin

News Reporter

Al­ny­lam Phar­ma­ceu­ti­cals is so pleased with 18-month da­ta from its Phase III tri­al in­ves­ti­gat­ing On­pat­tro as a treat­ment of AT­TR car­diomy­opa­thy that it

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times